247 related articles for article (PubMed ID: 12123283)
1. The promyelocytic leukemia nuclear body: sites of activity?
Eskiw CH; Bazett-Jones DP
Biochem Cell Biol; 2002; 80(3):301-10. PubMed ID: 12123283
[TBL] [Abstract][Full Text] [Related]
2. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
3. PML bodies: a meeting place for genomic loci?
Ching RW; Dellaire G; Eskiw CH; Bazett-Jones DP
J Cell Sci; 2005 Mar; 118(Pt 5):847-54. PubMed ID: 15731002
[TBL] [Abstract][Full Text] [Related]
4. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.
Doucas V; Tini M; Egan DA; Evans RM
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2627-32. PubMed ID: 10077561
[TBL] [Abstract][Full Text] [Related]
5. The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body.
Boisvert FM; Kruhlak MJ; Box AK; Hendzel MJ; Bazett-Jones DP
J Cell Biol; 2001 Mar; 152(5):1099-106. PubMed ID: 11238464
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus.
Muratani M; Gerlich D; Janicki SM; Gebhard M; Eils R; Spector DL
Nat Cell Biol; 2002 Feb; 4(2):106-10. PubMed ID: 11753375
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells.
Weis K; Rambaud S; Lavau C; Jansen J; Carvalho T; Carmo-Fonseca M; Lamond A; Dejean A
Cell; 1994 Jan; 76(2):345-56. PubMed ID: 8293468
[TBL] [Abstract][Full Text] [Related]
8. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
Müller S; Matunis MJ; Dejean A
EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
[TBL] [Abstract][Full Text] [Related]
9. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
10. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.
Bernardi R; Pandolfi PP
Nat Rev Mol Cell Biol; 2007 Dec; 8(12):1006-16. PubMed ID: 17928811
[TBL] [Abstract][Full Text] [Related]
11. Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.
Tatemichi Y; Shibazaki M; Yasuhira S; Kasai S; Tada H; Oikawa H; Suzuki Y; Takikawa Y; Masuda T; Maesawa C
Cancer Sci; 2015 Jul; 106(7):848-56. PubMed ID: 25891951
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.
Mologni L; Marchesi E; Nielsen PE; Gambacorti-Passerini C
Cancer Res; 2001 Jul; 61(14):5468-73. PubMed ID: 11454693
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
14. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.
Roussigne M; Cayrol C; Clouaire T; Amalric F; Girard JP
Oncogene; 2003 Apr; 22(16):2432-42. PubMed ID: 12717420
[TBL] [Abstract][Full Text] [Related]
15. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies.
Koken MH; Reid A; Quignon F; Chelbi-Alix MK; Davies JM; Kabarowski JH; Zhu J; Dong S; Chen S; Chen Z; Tan CC; Licht J; Waxman S; de Thé H; Zelent A
Proc Natl Acad Sci U S A; 1997 Sep; 94(19):10255-60. PubMed ID: 9294197
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML.
Borden KL; Lally JM; Martin SR; O'Reilly NJ; Solomon E; Freemont PS
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1601-6. PubMed ID: 8643677
[TBL] [Abstract][Full Text] [Related]
17. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
18. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies.
Borden KL
Mol Cell Biol; 2002 Aug; 22(15):5259-69. PubMed ID: 12101223
[No Abstract] [Full Text] [Related]
19. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
Giannì M; de Thé H
Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
[TBL] [Abstract][Full Text] [Related]
20. Role and fate of PML nuclear bodies in response to interferon and viral infections.
Regad T; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7274-86. PubMed ID: 11704856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
